Avalon Globocare Corp (ALBT)

NASDAQ
0.3420
-0.0280(-7.57%)
  • Volume:
    34,614
  • Day's Range:
    0.3400 - 0.3634
  • 52 wk Range:
    0.3400 - 1.0700
Trading near 52-week Low

Avalon Globocare has hit the lowest price it has traded for over the last year (52 week period). This is a technical indicator that can be used to analyze the stock's current value and predict future price movement.

ALBT Overview

Prev. Close
0.37
Day's Range
0.34-0.3634
Revenue
1.41M
Open
0.34
52 wk Range
0.34-1.07
EPS
-0.131
Volume
34,614
Market Cap
34.02M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
200,826
P/E Ratio
-3.20
Beta
0.806
1-Year Change
-61%
Shares Outstanding
99,464,439
Next Earnings Date
-
What is your sentiment on Avalon Globocare?
or
Vote to see community's results!

Avalon Globocare Corp News

Avalon Globocare Corp Company Profile

Avalon Globocare Corp Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People’s Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Up soon
    2
    • once phase ii and iii returns positive results on s-layer based nasal spray vaccine delivery. we'll see $10 faster than you can imagine!
      1
      • Great news. Soon 2$
        1
        • Just closed on its 3rd straight positive day in a row. $1.67 still seems really cheap.
          0
          • Avalon GloboCare NASDAQ AVCO is trending notable attention from Doctors around the world for his work on CAR-T cancer treatments. The stock closed up over 9% today so do your homework and don't miss another huge run from AVCO. http://www.drtranbiosci.com/?m=1
            0
            • Charles Schwab just bought 117,000 shares last week. Institutions like Bank of NY Mellon Corp and Even Black Rock have taken large Positions. The current stock price suggests that retail investors are missing something because banks institutions and index funds of quietly been accumulating while the stock is under a $1.60. Do your own homework on this one.
              0
              • Is this worth keeping?
                1
                • Q4 earning is coming soon!
                  0
                  • Q4 earning is coming soon!
                    0
                    • Its moving now
                      0